Posted on September 4th, 2010 by Health News
Members of the Prostate Cancer Roundtable, consisting of America’s Leading Prostate Cancer Organizations, are asking President Obama to place a blue ribbon on the White House and light the White House blue in the evenings in recognition of Prostate Cancer Awareness Month in September. This visible show of support for prostate cancer awareness by the [...]
No Comments »
Filed under: Men's Health
Posted on September 3rd, 2010 by Health News
As the summer comes to a close, I wanted to update you on the Company’s accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges [...]
No Comments »
Filed under: Pharmacy News
Posted on September 3rd, 2010 by Health News
Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
No Comments »
Filed under: Pharmacy News
Posted on September 3rd, 2010 by Health News
Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys’ initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics’ technology.
No Comments »
Filed under: Pharmacy News
Posted on September 3rd, 2010 by Health News
Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.
No Comments »
Filed under: Pharmacy News
Posted on September 3rd, 2010 by Health News
LifeVantage Corporation, the maker of Protandim®, a clinically proven, science-based therapy for oxidative stress, announced today that a new peer-reviewed study involving Protandim® was published in the scientific journal PLoS ONE. The study, conducted by researchers at Louisiana State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress tumors in [...]
No Comments »
Filed under: Pharmacy News
Posted on September 3rd, 2010 by Health News
Heard the one about how aspartame single-handedly caused the Gulf War syndrome? In recent years, outlandish allegations – often spread via the Internet by individuals who have little scientific or medical expertise – have tried to link the low-calorie sweetener to every ailment ranging from Multiple Sclerosis and Parkinson’s disease to cancer and weight gain. [...]
No Comments »
Filed under: Pharmacy News
Posted on September 2nd, 2010 by Health News
Cancer Research UK’s Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat.
No Comments »
Filed under: Pharmacy News
Posted on September 2nd, 2010 by Health News
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.
No Comments »
Filed under: Pharmacy News
Posted on September 2nd, 2010 by Health News
Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting [...]
No Comments »
Filed under: Pharmacy News
